Paulaj, I think your views on the costs are valid but the loss is in line with forecasts and expectations. The test will come on the cost side as they look to service the larger order book that they now have. History would suggest they will struggle to maintain cost discipline but we live in hope.
I am however curious with respect to the leading edge technology advancements you reference. What areas do you feel they should be advancing ? My own view is they should now focus on profitability and when needed they can buy in any advancement. As Cogstate and others have proven over the years, being at the very leading edge is neither profitable nor commercial. You want to be at the leading edge of mainstream adoption and given over 50% of cognitive testing are still done using pencil and paper it seems they still have runway here ? On the healthcare side it seems to me Cognigram is one of only handful of validated and licensed test that could be rolled out in scale with the healthcare system and as a product it is "good enough" to serve as a triage tool for AD. Would appreciate your thoughts in this area.
CGS Price at posting:
37.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)